PASC
Longitudinal Study of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Post-Acute Sequelae of COVID-19 (PASC)
Sponsor study identifier
Secondary identifiers
NIH
observational
500
1 country
1
Study Start
September 4, 2024
Actual (reported)Primary Completion
December 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This study will examine how common Long COVID is and how symptoms may persist over time in people who have previously had COVID-19. Researchers will collect information about participants' health and symptoms through questionnaires and may collect saliva and other non-invasive oral samples. The study will also examine biological factors in these samples that may be associated with persistent symptoms. The goal is to better understand why some people develop Long COVID and identify factors that may help predict who is more likely to experience persistent symptoms.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 4, 2024
Actual (reported)August 19, 2026
Actual (reported)August 24, 2026
Actual (reported)December 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 31, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Salivary Proteomic Profile
Unbiased and untargeted mass spectrometric analysis of saliva proteins to obtain a specific proteomic profile
During active infection through three months post infection
Salivary Metabolomic Profile
Unbiased and untargeted mass spectrometric analysis of saliva metabolites to obtain a specific metabolomic profile
During active infection through three months post infection
Validated Health Questionnaires: SBQ-LC (Symptom Burden Questionnaire - Long COVID)
This instrument assesses PASC-related symptom burden following COVID-19 infection. Scoring: 0- None, 1- Mild, 2- Moderate, 3-Severe - Higher score reflects greater severity.
During active infection through three months post infection
Validated Health Questionnaire: C19-YRS (COVID-19 Yorkshire Rehabilitation Scale)
This instrument assesses the long-term physical, cognitive, and psychological outcomes following COVID-19 infection. Scoring: 0-10 numerical scale; a higher score reflects greater severity.
During active infection through three months post infection
Validated Health Questionnaire: EFTER-COVID survey
Adults who have previously had COVID-19 and may be experiencing ongoing symptoms or changes in their health following infection.
Other:
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Adults aged 18 to 75 years with a history of SARS-CoV-2 infection will be enrolled. The study will include individuals with and without persistent symptoms following infection to characterize the prevalence, severity, and persistence of PASC and identify demographic, clinical, and biological factors associated with Long COVID. Approximately 500 participants will be enrolled at the University of North Carolina at Chapel Hill.
University of North Carolina
Chapel Hill, North Carolina, 27599-7555, United States
Salivary samples
Laura Jacox, PhD, DMD, MS
University of North Carolina, Chapel Hill
First Submitted
August 19, 2026
First Posted
August 24, 2026
Study Start
September 4, 2024
Actual (reported)Primary Completion
December 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This instrument assesses the long-term physical, cognitive, and psychological outcomes following COVID-19 infection. EFTER is not an abbreviation; it is the name of the survey, and it is the Danish word for "After" Scoring: Yes/No - Higher score reflects More affected.
During active infection through three months post infection
Contact the study team to confirm eligibility.
Study Completion
December 31, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
September 28, 2026
Record last verified: 2026-09
Individual participant data will not be shared with other researchers outside of the approved study team. De-identified data may be used for future research in accordance with the informed consent, applicable regulations, and institutional policies.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: